Associated Genetic Biomarkers
CTGF is altered in 0.00% of all cancers with diffuse astrocytoma having the greatest prevalence of alterations .
The most common alteration in CTGF is CTGF-ROS1 Fusion (0.00%) .
CTGF status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains CTGF status as an inclusion criterion, 1 is phase 1 (0 open).
Trials with CTGF status in the inclusion eligibility criteria most commonly target lymphoma and malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is CTGF Expression .
Crizotinib and dasatinib are the most frequent therapies in trials with CTGF as an inclusion criteria .
Significance of CTGF in Diseases
CTGF is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains CTGF status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) .
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.